A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-06-07

Study Completion Date

2019-03-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study was a companion study to CLEE011A2404 which provided the opportunity for the collection of tumor tissue samples to better understand relevant mutations and the mechanisms responsible for resistance to treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

NCT04657679

Breast Cancer

TERMINATED PHASE4

Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples

NCT01034033

Breast Cancer Ovarian Cancer Gynecologic Cancers +1 more

RECRUITING

Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

NCT04190667

Epithelial Ovarian Cancer Chinese Homologous Recombination Deficiency +3 more

UNKNOWN

A Training Set for the HRD Model in EOC

NCT04651933

Epithelial Ovarian Cancer BRCA Mutation Loss of Heterozygosity +3 more

UNKNOWN

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation

NCT03265496

Nsclc

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a multicenter, non-treatment based companion sample collection protocol conducted in the US only. This protocol sought to evaluate the aberrations of common pathways for newly diagnosed HR+/HER2- advanced breast cancer tumors and responses to ribociclib in diverse patient populations. This companion sample collection protocol was available for all US patients enrolled on CLEE011A2404 (CompLEEment-1) and did not alter the planned treatment. Tumor collection required for this study occurred at two time points: at baseline/screening and upon the development of progressive disease as shown in the protocol. Patients eligible for this companion study were required to sign an optional additional consent form at the time of enrolling into the core trial.

After eight patients had consented and samples had been taken, it was determined that the companion study protocol had not been properly initiated or monitored at the sites. This was determined to be a significant GCP violation and the clinical team made the decision to terminate the trial. In addition to the GCP issues, enrollment had been closed to the core study so enrolling additional patients was no longer possible. The limited number of samples would not provide any meaningful analysis. The samples were never analyzed. The study was not terminated due to safety or efficacy concerns. Samples collected were either destroyed or will be retained for up to 15 years based upon the decision of the patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ribociclib + letrozole

ribociclib with letrozole per the core study

Group Type EXPERIMENTAL

Ribociclib

Intervention Type DRUG

ribociclib + letrozole

letrozole

Intervention Type DRUG

ribociclib + letrozole

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ribociclib

ribociclib + letrozole

Intervention Type DRUG

letrozole

ribociclib + letrozole

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent was to have been obtained prior to any baseline/screening procedures.
* Patients eligible for this companion sample collection protocol sample collection protocol must have met all inclusion in CLEE011A2404.